Tricyclic compounds having sPLA2-inhibitory activities
AssigneeShionogi & Co., Ltd.
InventorsMitsuaki Ohtani, Masahiro Fuji, Tetsuo Okada, Makoto Adachi, Tomoyuki Ogawa
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound having sPLA2 inhibiting activity. The compound represented by the formula (I): wherein R1 is (a) C1 to C20 alkyl, C2 to C20 alkenyl, C2 to C20 alkynyl, carbocyclic groups, heterocyclic groups or the like; R2 is CONH2 or CONHNH2; one of R3 and R4 is —(L2)-(acidic group) wherein L2 is a group connecting with an acid group and the length of the connecting groups 1 to 5 atoms, and the other is a hydrogen atom; its prodrug, their pharmaceutically acceptable salt, or solvate thereof.
Claims10
A compound represented by the formula (I):
- wherein R1 is a group selected from (a) C1 to C20 alkyl, C2 to C20 alkenyl, C2 to C20 alkynyl, carbocyclic groups, and heterocyclic groups, (b) the groups represented by (a) each substituted independently with at least one group selected from non-interfering substituents, or (c) —(CH2)m—R5 wherein m is an integer from 1 to 6, and R5 is a group selected from the groups (a) and (b);
- one of R3 and R4 is —(L2)-(acidic group) wherein L2 is represented by the formula:
- wherein M is —CH2—, —O—, —N(R15)—, or —S—;
- R13 and R14 are each independently a hydrogen atom, C1 to C10 alkyl, aryl, aralkyl, carboxy, or halogens, wherein R15 is a hydrogen atom or C1 to C6 alkyl;
- and acidic group is represented by the formula:
- wherein R16 is hydrogen atom, a metal, or C1 to C10 alkyl;
- R17 is independently a hydrogen atom or C1 to C10 alkyl;
- h is an integer from 1 to 8 and the other is a hydrogen atom,
- A ring is a group represented by the formula:
- wherein R2 is CONH2 or CONHNH2;
- R18, R19, R20, R21, R22, and R23 are each independently a hydrogen atom, or lower alkyl;
- R24 and R25 are each independently a hydrogen atom, C1 to C6 alkyl, aryl, a halogen or aralkyl;
- its prodrug, their pharmaceutically acceptable salt, or hydrate thereof.
A compound represented by the formula (II):
- wherein R24, R25, and A ring are as defined above;
- R6 is —(CH2)m—R9 wherein m is an integer from 1 to 6, and R9 is (d) a group represented by the formula:
- wherein a, c, e, n, q, t and v are each independently an integer from 0 to 2;
- R10 and R11 are each independently selected from a halogen, C1 to C10 alkyl, C1 to C10 alkyloxy, C1 to C10 alkylthio, optionally substituted phenyl, optionally substituted heteroaryl and C1 to C10 haloalkyl;
- α is an oxygen atom or a sulfur atom;
- β is —CH2— or —(CH2)2—;
- γ is an oxygen atom or a sulfur atom;
- b is an integer from 0 to 3, d is an integer from 0 to 4;
- f, p, and w are each independently an integer from 0 to 5;
- r is an integer from 0 to 7;
- and u is an integer from 0 to 4, or R9 is (e) a member of (d) substituted with at least one substituent selected from the group consisting of C1 to C6 alkyl, C1 to C6 alkyloxy, C1 to C6 haloalkyloxy, C1 to C6 haloalkyl, phenyl, and a halogen;
- one of R7 and R8 is —(L3)—R12 wherein L3 is represented by the formula:
- wherein M is —CH2—, —O—, —N(R15)—, or —S—;
- R13 and R14 are each independently a |hydrogen atom, C1 to C10 alkyl, aryl, aralkyl, carboxy, or a halogen, and R15 is a hydrogen atom or C1 to C6 alkyl;
- and
- R12 is represented by the formula:
- wherein R16 is hydrogen atom, a metal, or C1 to C10 alkyl;
- R17 is independently a hydrogen atom or C1 to C10 alkyl;
- h is an integer from 1 to 8;
- its prodrug, their pharmaceutically acceptable salt, or hydrate thereof.
A compound represented by the formula (III):
- wherein R10, A ring, and m are as defined above,
- its prodrug, their pharmaceutically acceptable salt, or hydrate thereof.
Dependencies are inferred from the claim text.